Vir Biotechnology Inc (NASDAQ:VIR) shares, rose in value on Thursday, March 06, with the stock price down by -1.82% to the previous day’s close as strong demand from buyers drove the stock to $8.07.
Actively observing the price movement in the last trading, the stock closed the session at $8.22. Referring to stock’s 52-week performance, its high was $14.45, and the low was $6.56. On the whole, VIR has fluctuated by -16.76% over the past month.
With the market capitalization of Vir Biotechnology Inc currently standing at about $1.11 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 8.59M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VIR’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of VIR currently trading nearly -11.53% and -13.34% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.19, while the 7-day volatility ratio is showing 6.81% which for the 30-day chart, stands at 6.70%. Furthermore, Vir Biotechnology Inc (VIR)’s beta value is 1.06, and its average true range (ATR) is 0.64.
A comparison of Vir Biotechnology Inc (VIR) with its peers suggests the former has fared considerably weaker in the market. VIR showed an intraday change of -1.82% in last session, and over the past year, it shrunk by -27.88%%.
Data on historical trading for Vir Biotechnology Inc (NASDAQ:VIR) indicates that the trading volumes over the past 3 months, they’ve averaged 2.06 million. According to company’s latest data on outstanding shares, there are 136.96 million shares outstanding.
Nearly 36.28% of Vir Biotechnology Inc’s shares belong to company insiders and institutional investors own 51.38% of the company’s shares. The stock has risen by 9.95% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VIR stock heading into the next quarter.
